Search - tctmd.com

Displaying 1 - 20 of 44

Sort: Relevancy | Date

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

News Conference News HRS 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

April 29, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

News Conference News TCT 2024

TAVR UNLOAD: No Rush to Do TAVI in HFrEF Patients With Moderate AS

October 28, 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

News Conference News EACTS 2024

At EACTS 2024, Surgeons and Cardiologists Move Past EXCEL Firestorm

Yael L. Maxwell

October 22, 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

News Conference News ACC 2024

Vaping Linked to Higher Risk of HFpEF, NIH Data Show

April 12, 2024

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

News Conference News AHA 2023

DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI

November 11, 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

News Conference News HFSA 2023

STRONG-HF Analysis: Safety Events Common but Manageable in GDMT Optimization

October 18, 2023

PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization

News Conference News HFSA 2023

PA Pressure Monitoring Benefits HF Patients With No Recent Hospitalization

October 12, 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

News Conference News ESC Heart Failure 2023

SGLT2i Still Underprescribed in HFrEF, New US Analysis Confirms

June 06, 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

News Conference News THT 2023

PCI’s Role for Patients With HFrEF and Extensive CAD: Experts Debate

March 20, 2023

Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies

News Conference News ACC 2023

Too Many HF Patients Exiting Rural Hospitals Miss Out on Endorsed Therapies

February 23, 2023

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

October 07, 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

September 16, 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 07, 2022

Aficamten Safe, Effective for Up to 6 months in Obstructive HCM: REDWOOD-HCM OLE

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

May 31, 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

May 22, 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

April 07, 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

April 03, 2022

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

News Conference News PCR London Valves 2021

Good Results but Small Numbers With JenaValve Trilogy in Severe AR

Michael O'Riordan

November 26, 2021

TAVI Registries Offer Outcome Clues as Low-Risk Numbers Climb

News Conference News EACTS 2021

TAVI Registries Offer Outcome Clues as Low-Risk Numbers Climb

October 20, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.